Evidence map›Paper›PMID 21594779›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2011

Nasal potential difference measurements to assess CFTR ion channel activity.

Steven M Rowe, John Paul Clancy, Michael Wilschanski

Registry-linked trialAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07402434 (Advanced Diagnostic Validation and Novel Clinical Evaluation Across the CFTR Spectrum), which is not on this map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07402434 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Advanced Diagnostic Validation and Novel Clinical Evaluation Across the CFTR Spectrum (ADVANCE-CFTR): a Prospective Study of CFTR Functional Assays, Including Rectal Organoids, to Improve the Accuracy of Diagnosing Cystic Fibrosis.

TypeobservationalSponsorRoyal Brompton & Harefield NHS Foundation TrustRan2026 to 2028Enrolled80ConditionsCystic Fibrosis (CF), CFTR-related DisordersArmsRectal Biopsy, Rectal biopsy taken opportunistically during endoscopy procedure for other reasons., Blood test for CFTR Genotyping
3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Article
  3. Toward in vivo bronchoscopic functional CFTR assessment using a short circuit current measurement probe.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  4. Review
  5. Article
  6. Personalized CFTR Modulator Therapy forInternational journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
  9. Assays of CFTR Function In Vitro, Ex Vivo and In Vivo.International journal of molecular sciences · 2022
    Review
  10. Article
  11. Article
  12. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.American journal of physiology. Gastrointestinal and liver physiology · 2021
    Article
  13. Amphotericin B induces epithelial voltage responses in people with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Optical Nanosensors forAnalytical methods : advancing methods and applications · 2020
    Article
  19. Novel therapeutic approaches for the management of cystic fibrosis.Multidisciplinary respiratory medicine · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Steven M RoweDepartment of Medicine, University of Alabama, Birmingham, AL 35294-0006, USA. smrowe@uab.edu
John Paul Clancy
Michael Wilschanski

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
Premature Termination Codon SuppressionK23DK075788 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2006 to 2010
$638k
Mechanistic Basis Underlying Protein Repair of CFTR Nonsense MutationsR03DK084110 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2009 to 2010
$146k
NIDDK NIH HHS 1K23DK075788-01NIDDK NIH HHS 1P30DK072482-01A1NIDDK NIH HHS 1R03DK084110-01NIDDK NIH HHS K23 DK075788NIDDK NIH HHS P30 DK072482NIDDK NIH HHS R03 DK084110
6 · The paper itself

Abstract

The Nasal potential difference measurement is used to measure the voltage across the nasal epithelium, which results from transepithelial ion transport and reflects in part CFTR function. The electrophysiologic abnormality in cystic fibrosis was first described 30 years ago and correlates with features of the CF phenotype. NPD measurement is an important in vivo research and diagnostic tool, and is used to assess the efficacy of new treatments such as gene therapy and ion transport modulators. This chapter will elaborate on the electrophysiological principles behind the test, the equipment required, the methods, and the analysis of the data.

Indexed as

Membrane PotentialsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansNasal MucosaPerfusionCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID21594779
PMCPMC3760477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.